ICD 2025: New data demonstrate Nemluvio®'s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years
Zug, Switzerland:
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years 1
Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis 1-3
This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4
Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617336479/en/
'These promising data go even further in highlighting the extensive benefits of Nemluvio. As this treatment becomes available in more countries around the world, it's highly encouraging to see its robust evidence base continue to expand and strengthen.'
BALDO SCASSELLATI SFORZOLINI, M.D., PHD.
GLOBAL HEAD OF RESEARCH & DEVELOPMENT
GALDERMA
Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on patients' quality of life.5-7 Nemluviois the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31.8,9,10 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation, skin barrier dysfunction, and fibrosis in prurigo nodularis.8-11 It is also the first and only biologic approved for prurigo nodularis as well as atopic dermatitis with four-week dosing intervals from the start of treatment.9,10
The OLYMPIA long-term extension study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and includes 508 patients from the phase II trial or the phase III OLYMPIA 1 and 2 trials.1 Results show that treatment with Nemluvio is associated with sustained and clinically meaningful improvements in symptoms of prurigo nodularis during prolonged treatment up to two years.1 At Week 100 in evaluable patients, the interim analysis shows that: More than 90% and 70% achieved at least a four-point improvement in itch, and being itch free or nearly itch free respectively, as measured by the Peak-Pruritus Numerical Rating Scale 1
At least 80% achieved 76‑100% healed pruriginous lesions 1
Approximately 75% reached clearance or almost-clearance of skin nodules when assessed using the Investigator's Global Assessment score1
Nemluvio was well tolerated in the long-term treatment of prurigo nodularis and no new safety signals were identified in this study to date.1
'These impressive results give us even more confidence in the value of nemolizumab – a much-needed innovative medicine that has the potential to deeply impact the prurigo nodularis treatment landscape. With this new treatment now approved in multiple markets including the EU and U.S., I'm thrilled to be able to see its meaningful impact in the real world.'
PROF. SONJA STÄNDER
LEAD INVESTIGATOR OF THE OLYMPIA STUDIES IN EUROPE
UNIVERSITY HOSPITAL MUNSTER, GERMANY
This follows presentation of results from the ARCADIA long-term extension study at the RAD Conference earlier this month, which showed that treatment with Nemluvio was well tolerated and associated with sustained and increased improvements in symptoms of atopic dermatitis during prolonged treatment up to two years.4
Nemluvio was first approved in August 2024 by the United States Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis.9 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.9 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including the European Commission. Additional reviews and submissions are ongoing.
Galderma will also host a symposium at ICD, exploring the latest advances in addressing itch in both prurigo nodularis and atopic dermatitis. Separately, the company will share new data from across its Therapeutic Dermatology portfolio in acne, non-melanoma skin cancer, and rosacea.
More details on Galderma's scientific presentations at ICD can be found here.
About Nemluvio
Nemluviowas initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.12,13
About prurigo nodularis
Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.5-7 It is an underrecognized and underdiagnosed skin condition, and there are limited studies investigating its prevalence.11,14,15
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References Ständer S, et a. Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis. Presented at International Congress of Dermatology; June 18-21, 2025; Rome, Italy. ClinicalTrials.Gov. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed May 2025 ClinicalTrials.Gov. Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed May 2025 Silverberg, JI, et al. Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Presented at Revolutionizing Atopic Dermatitis Conference 2025; June 6-7; Nashville, United States. Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183 Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570 Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042 Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013 Nemluvio U.S. Prescribing Information. Available online. Accessed May 2025 Nemluvio European Medicines Agency. Summary of Product Characteristics. Available online. Accessed May 2025 Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555-022-00782-2 Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed May 2025 Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed May 2025 Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/j.jdin.2020.10.009 Huang AH, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.e4. doi: 10.1016/j.jid.2019.07.697
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617336479/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
New $7.1 million heart, vascular center opens in Woodbridge
PRINCE WILLIAM COUNTY, Va. () — A new facility has officially opened its doors in Woodbridge, dedicated to outpatient heart and vascular patients. The center was brought to life after Sentara Health, Carient Heart & Vascular and Polaris Heart & Vascular Clinic partnered to create the new state-of-the-art facility. The $7.1 million is the first of its kind in Northern Virginia and was designed and built with the latest advancements in outpatient cardiac care. FDA's top vaccine regulator departs amid conservative criticism Officials noted that the facility was designed to improve access, patient experience and affordability for the growing community in Prince William County. The center will offer cardiac catheterizations, percutaneous coronary interventions, electrophysiology procedures to include pacemakers, ICD implants and more. 'What this means to patients is that they can now have cardiac procedures done in an outpatient setting without having to go through the often-rigorous process of a hospital visit, offering greater convenience, comfort, and privacy to people in this area,' said SNVMC President Jeff Joyner. 'Sentara is proud to work with our partners to bring such innovation to Northern Virginia.' Officials noted that procedures are completed as an outpatient procedure, and patients go home the same day. 'Another significant advantage for patients is the typically lower out-of-pocket costs compared to a hospital setting,' added Jessica Mountjoy, the center's administrator. Staff at the Northern Virginia Heart & Vascular Center completed its first patient procedure on July 24. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Upturn
3 days ago
- Business Upturn
IKS Health Reports Robust Q1 FY26 Results with 16% Year-over-Year Revenue Growth and 59% Year-over-Year PAT Increase
By Business Wire India Published on July 31, 2025, 23:11 IST Inventurus Knowledge Solutions Limited (NSE: IKS), a technology-enabled healthcare solutions provider, today announced strong growth in Q1 FY26. IKS Health, a care enablement platform focused on supporting physician enterprises primarily in the US, reported its financial results for the quarter ended June 30, 2025. Business Wire India Revenue growth in Q1 16% YoY in INR, 13% YoY in USD Q1 EBITDA up 36% YoY; 5% QoQ PAT up 59% YoY; 3% QoQ Inventurus Knowledge Solutions Limited (NSE: IKS), a technology-enabled healthcare solutions provider, today announced strong growth in Q1 FY26. IKS Health, a care enablement platform focused on supporting physician enterprises primarily in the US, reported its financial results for the quarter ended June 30, 2025. 'Our performance this quarter reflects the continued momentum in our business and the stickiness of our integrated tech-led care enablement platform built on strong client relationships, scalable solutions, and disciplined execution,' said Sachin K. Gupta, Founder & Global CEO, IKS Health. 'The sustained revenue growth at 16% and improvement of EBITDA margin for the combined entity to 32% demonstrates the impact of our technology-led care enablement platform and global delivery capabilities. As we move forward, our focus remains on deepening client value, investing in innovation, and scaling our platform to address the evolving needs of the healthcare ecosystem.' Nithya Balasubramanian, CFO, IKS Health, said, 'We delivered a strong financial performance in Q1 FY26, driven by consistent revenue growth and continued focus on operational efficiency. Our EBITDA margin improvement reflects disciplined cost management, scalability of our platform, and prudent capital allocation. As we move ahead, we remain committed to sustaining healthy margins while strategically investing in capabilities that drive long-term value creation.' Key Financial Highlights: Q1FY26 ended on June 30, 2025 Revenue at INR 7,401 million (15.6% YoY / + 2.2% QoQ growth) EBITDA at INR 2,378 million at 32.1% of revenue (36.3% YoY / +5.1% QoQ growth) PAT at INR 1,515 million at 20.5% of revenue (58.7% YoY / 2.5% QoQ growth) Adjusted PAT at INR1,682 million at 22.7% of revenue (51.4% YoY / 2.2% QoQ growth) Business Highlights: IKS Health continues to expand its reach and impact through strategic partnerships. The following highlights key collaborations, including both new alliances and the expansion of existing relationships, that demonstrate the company's commitment to driving financial outcomes, enabling growth, and enhancing clinical efficiencies for healthcare providers. Mission Community Hospital: New partnership to drive financial outcomes and accountability with end-to-end revenue cycle across the hospital acute care and ambulatory surgery spaces Bicycle Health: New partnership leveraging IKS to manage revenue cycle, enabling rapid growth and scale of the virtual network OrthoNY: Expanded partnership to introduce IKS Virtual Clinical Assistant at a growing specialty network to take on administrative tasks and support clinical efficiencies in addition to existing RCM services. A top 5 Health System: Expanded partnership for coding to drive revenue performance and mitigate operational inefficiencies. Recognition & Awards IKS Health received the below notable recognitions: ET HRWorld Exceptional Employee Experience – Large Scale Award BW CFO Finance & Strategy Excellence Awards Excellence in Mergers and Acquisitions Award – Gold (Organizational Category) Best Woman CFO, Nithya Balasubramanian (Individual Category) Safe Harbour Certain statements in this release concerning our future growth prospects may be seen as forward-looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. It is not possible to undertake to update any such statement that may have been made from time to time. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Newsweek
4 days ago
- Newsweek
America's Leading Doctors 2025
Statista and Newsweek have partnered to provide patients with a comprehensive resource to aid in finding the best doctors in the United States across 15 medical fields for their specific treatment needs. America's Leading Doctors awards the top 175-200 doctors in the following medical specialties: Cardiothoracic surgery, Cataracts surgery, Colorectal surgery, Foot and Ankle surgery, Glaucoma surgery, Hand surgery, Hip surgery, Knee surgery, Mohs surgery, Pain Management, Retina surgery, Shoulder surgery, Spine surgery, Sports Medicine, and Vascular surgery. The lists are based on four data sources: Doctor performance data : Analysis of 2022-2023 performance benchmark data based on Medicare Fee-for-Service claims and commercial data sourced from Arcadia Online survey by state : Online survey of thousands of medical experts (doctors, managers/ administrators, and other medical professionals) across 20 states with knowledge in the respective medical field Quality Score : Quality of care rating by peers Certifications: Certifications from several American medical and surgical certification boards Doctor performance data: Sixty percent of the total score is based on exclusive performance benchmark data sourced from Arcadia. Doctors' performance was evaluated based on Episode of care data, including all medical episodes relevant to the respective specialty, as well as referral volume data. The following episodes are example cases for the specialty of Hand surgery: Joint or tendon inflammation of the finger/wrist/hand Joint cyst Inflammation or injury of the tendons or ligaments in the arm Fracture/dislocation treatment arm/wrist/hand Carpal tunnel & related syndromes The volume of episodes performed and the following six outcome measures per episode were considered: Average LOS (Days) of Institutional Long-term Stay ER Visits per 1,000 Episodes Mortality Rate Complications by Episode Unplanned Readmissions per 1,000 Episodes Average Episode Payment Scores were assigned for volume of episodes and outcomes measures per episode by comparing each doctor's performance for each metric relative to all other doctors of the same specialty practicing in the same state in a given year. Additionally, physicians who treated a particularly high number of patients for one or more relevant episodes within their state in 2023 received a High Performance award in the form of 1, 2, or 3 ribbons. Online survey by state From March to May 2025, Statista invited thousands of medical experts (physicians, managers/administrators, and other medical with knowledge in the respective medical field) in the 20 U.S. states with the highest number of doctors (varies per specialty) to an online survey. The survey was also promoted on Participants were asked to recommend doctors in their own state and in any of the other U.S. states included in the survey. The reason for recommendation (e.g., well-known specialist), the work experience of the participant, and the order of recommendation were taken into account. They were also able to specify a 'peers' choice' standout treatment for each recommended doctor. Recommendations from peers constitute 27.5% of the total doctor score. Quality Score For within-state recommendations, participants were asked to assess the quality of care (e.g., treatments, follow-up care, use of most recent equipment) and professional expertise (e.g., knowledge in medical field) of the doctor. For each recommended physician, participants rated the quality dimensions on a scale from 1 ('poor') to 10 ('excellent'). A quality score was calculated for each physician with within-state recommendations. This score accounts for 7.5% of the total score. Certifications Certifications from American medical and surgical certification boards were included in the evaluation. For example, in the specialty of Hand Surgery: American Board of Orthopaedic Surgery: Orthopaedic Surgery Certification Subspecialty Certification in 'Surgery of the Hand' American Board of Plastic Surgery: Hand Surgery Certification Certifications contribute 5% to the total score. Notes regarding results tables: Hospital affiliation for each physician was determined by patient volume. For physicians with no data related to hospital affiliation, affiliation was determined by desk research. If the specified affiliated hospital has been awarded in a hospital ranking, it is listed under 'Affiliated with a Newsweek Best Hospital'. Up to three ribbons were awarded for each episode based on each doctor's percentile rank for episode volume within their state. If a particular procedure was recommended frequently by peers, it is indicated under 'Peers' Choice'. The methodology overview is available here. The extended methodology is available here. Disclaimer The rankings are comprised exclusively of doctors that are eligible regarding the scope described in this article. A mention in the top lists is a positive recognition based on peer recommendations and available data sources at the time. The top lists are the result of an elaborate process which, due to the interval of data-collection and analysis, is a reflection of the past 12 months only. Furthermore, any events preceding or following the period June 25th, 2024 – June 24th, 2025, were not included in the metrics. As such, the results of these top lists should not be used as the sole source of information for future deliberations. The information provided in these top lists should be considered in conjunction with other available information about physicians or, if possible, accompanied by a visit to a hospital/physician's practice. The quality of physicians that are not included in the top lists are not disputed. About Statista R Statista R is a world leader in the creation of company, brand, and product rankings and top lists, based on comprehensive market research and data analysis: Statista R recognizes the best. With a team of over 100 expert analysts and in cooperation with more than 40 high profile media brands across all continents, Statista R creates transparency for consumers and business decision makers and helps companies build trust and recognition across a plethora of industries and product categories. Visit Statista R is a division of Statista. The leading data and business intelligence portal provides an extensive collection of statistics, reports, and insights on over 80,000 topics from 22,500 sources in 170 industries. Find out more at We may earn a commission from partner links on Newsweek, but commissions do not affect placement and have no influence on editor opinions or evaluations.
